Trials / Recruiting
RecruitingNCT06131450
A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-M07D1 | Administration by intravenous infusion |
Timeline
- Start date
- 2024-02-29
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2023-11-14
- Last updated
- 2025-09-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06131450. Inclusion in this directory is not an endorsement.